|
|
Science Sparks @ ACTREC
|
17th June 2024 |
Vol. No. 13 ; Issue No.635 |
|
Publications
|
1. Mhatre SS, Bragg F, Panse N, Judge PK, Manjrekar A, Burrett JA, Patil S, Davey Smith G, Kotkar L, Relton CL, Doibale P, Gadhave B, Chaturvedi P, Sherliker P, Jha P, Lewington S, Dikshit R (2024). Cohort Profile: Indian study of healthy ageing (ISHA-Barshi). International Journal of Epidemiology. 53(4): dyae079.
|
|
|
Interesting Reads
|
Edman NI, Phal A, Redler RL, Schlichthaerle T, Srivatsan SR, Ehnes DD, Etemadi A, An SJ, Favor A, Li Z, Praetorius F, Gordon M, Vincent T, Marchiano S, Blakely L, Lin C, Yang W, Coventry B, Hicks DR, Cao L, Bethel N, Heine P, Murray A, Gerben S, Carter L, Miranda M, Negahdari B, Lee S, Trapnell C, Zheng Y, Murry CE, Schweppe DK, Freedman BS, Stewart L, Ekiert DC, Schlessinger J, Shendure J, Bhabha G, Ruohola-Baker H, Baker D (2024). Modulation of FGF pathway signaling and vascular differentiation using designed oligomeric assemblies. Cell.
|
|
Video of the Week
|
|
Future of AI in treating patients in Neurosurgery |
|
|
|
|
|
|
Do You Know?
In 2004, Azacitidine, an inhibitor of DNA methylation and a pioneering epigenetic therapy, became the first drug to gain US Food and Drug Administration (FDA) approval for the treatment of myelodysplastic syndrome.
|
|
|
|
2019 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|